EMC is in 70% of cases characterized by a t (9; 22) (q22; q12.2) translocation, fusing EWSR1 to NR4A3 and leading to constitutive expression of NR4A3. NR4A3 can also fuse to TAF15 on chromosome 17 q12.2 in 20% of cases, which contributes a transactivation domain as well. The gene discussed is NR4A3; the disease is extraskeletal myxoid chondrosarcoma.